Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616732 | 1.00 | PRCP (0.68) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL615383 | 1.00 | PRCP (0.68) | PRCPDPP7TLR2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4320225 | 0.98 | PRCP (0.66) | PRCPDPP7TLR2HTR2CHTR2B | |
| Acetic Acid SCHEMBL2183483 | 0.94 | PRCP (0.62) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL13990631 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL13359247 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL4710537 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL22019454 | 0.90 | PRCP (0.57) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL23169303 | 0.90 | — | — | |
| Trifluoroacetic Acid SCHEMBL3332141 | 0.88 | PRCP (0.56) | PRCPDPP7TLR2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117343128-A | Synthesis method of buserelin | 成都君诚康正生物科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-116655745-B | Application of intermediate in preparation of buserelin | 杭州湃肽生化科技有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-116655745-A | Application of intermediate in preparation of buserelin | 杭州湃肽生化科技有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-109438560-B | Liquid phase synthesis method of buserelin | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-110041407-B | Method for synthesizing dessertraline acetate based on Fmoc dipeptide | 南京肽业生物科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-108660131-B | Preparation method of immobilized nitrile hydratase and (S) -N-ethylpyrrolidine-2-formamide | 浙江工业大学 | 2020-07-21 | — | — | CN | claimed |
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | claimed |
| EP-1951746-A1 | SOLUTION-PHASE SYNTHESIS OF LEUPROLIDE AND ITS INTERMEDIATES | NANOKEM S.A. (UY) | 2008-08-06 | — | — | EP | claimed |
| WO-2007059921-A1 | SOLUTION-PHASE SYNTHESIS OF LEUPROLIDE AND ITS INTERMEDIATES | NANOKEM S.A. (UY) | 2007-05-31 | — | — | WO | claimed |
| US-20060217316-A1 | Method for the treatment of prostate cancer | GENIX THERAPEUTICS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2004087190-A1 | METHOD FOR THE TREATMENT OF PROSTATE CANCER | GENIX THERAPEUTICS INC. (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1390055-A2 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | Neurotell AG (CH) | 2004-02-25 | — | — | EP | claimed |
| EP-1358204-A1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Neurotell AG (CH) | 2003-11-05 | — | — | EP | claimed |
| WO-2002062830-A1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | claimed |
| WO-2002062372-A2 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| US-4493828-A | Use of thyrotropin releasing hormone and related peptides as poultry growth promotants | MERCK & CO., INC. (US) | 1985-01-15 | — | — | US | claimed |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-15 | — | — | US | disclosed |
| US-4493828-A | Use of thyrotropin releasing hormone and related peptides as poultry growth promotants | MERCK & CO., INC. (US) | 1985-01-15 | — | — | US | disclosed |
| EP-0130409-A2 | Slow-release composite and process for producing the same | Takeda Chemical Industries, Ltd. (JP) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | PRCP 664/4885DPP7 516/4885TLR2 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.